Publication:
Danazol in Indian haemophiliacs.

Simple item page
dc.contributor.authorSundar, S.
dc.contributor.authorMoorleedhur-Singh, G.S.
dc.contributor.authorDube, B.
dc.contributor.authorSingh, V.P.
dc.contributor.authorKumar, K.
dc.date.accessioned2025-04-19T05:03:46Z
dc.date.available2025-04-19T05:03:46Z
dc.date.issued1993
dc.description.abstractDanazol, 10 mg/kg/day (maximum 600 mg/day) was given in two divided doses for 14 days in 30 patients with haemophilia-A. Rise in factor-VIII level was observed in all the patients after one week of danazol therapy, irrespective of initial factor-VIII Levels. In haemophiliacs with less than 1% factor VIII level, rise was maximum (3-6 folds); mean factor-VIII level at 7th and 14th day of danazol therapy was 2.3 +/- 0.6% and 4.8 +/- 1.1%, respectively. Only marginal increase in factor-VIII was noted in haemophiliacs with initial factor-VII levels more than 3%. The raised level of factor-VIII persisted after stopping the therapy during the observation period of 2 more weeks, irrespective of initial levels. No adverse effect was observed during or after.
dc.identifier.doihttps://doi.org/nan
dc.identifier.issn45772
dc.identifier.urihttps://dl.bhu.ac.in/ir/handle/123456789/102525
dc.titleDanazol in Indian haemophiliacs.
dc.typeArticle
dspace.entity.typePublication
journal.titleThe Journal of the Association of Physicians of India
journalvolume.identifier.volume41

Files

Collections

1903-1999